Key Takeaways
- • Life sciences real estate market reached USD 3.75 billion in 2025 with projected growth to USD 6.76 billion by 2027, representing a compound annual growth rate of 6.76%, indicating sustained long-term structural demand despite near-term headwinds.
- • Vacancy rates have spiked to 27%—up 20.4 percentage points over three years—creating a tenant-favorable market with oversupply concentrated in newer buildings delivered since early 2022, signaling a dramatic shift from peak market conditions.
- • Lab leasing activity declined an average of 8% annually while venture capital funding to biotech fell 12% annually, with biotech's share of U.S. venture dollars collapsing from approximately 15% to 7% in recent quarters, establishing a direct correlation between VC deployment and lab demand.
- • AI-native biotechs now represent one-sixth of all biotech venture capital deals and demonstrate fundamentally different space requirements—leasing approximately one-third less space per employee than traditional biotechs with a 45-to-55 lab-to-office ratio, reshaping future real estate needs across the sector.
- • Top-tier workspaces in prime locations remain in demand, with five critical competitive dimensions defining regional positioning: artificial intelligence, start-up environments, biomanufacturing capacity, talent availability, and medtech infrastructure, according to major real estate analysts.
Summary
The life sciences real estate sector presents a paradoxical investment landscape in August 2024: significant long-term structural growth potential coexisting with pronounced near-term headwinds and market recalibration. The market has transitioned from an unprecedented growth phase into a period of dramatic oversupply, with the sector projected to reach USD 3.75 billion in 2025 and approach USD 6.76 billion by 2027, representing robust 6.76% compound annual growth.
The immediate market reality reflects substantial dislocation. Vacancy rates have surged to 27%—a 20.4 percentage point increase over three years—creating what major real estate firms characterize as a "tenant's market." This oversupply burden falls disproportionately on newer Class A buildings delivered since early 2022, when the sector peaked. Lab leasing activity slowed dramatically in Q1 2025, though 2024 showed some recovery momentum with a notable 41% year-over-year increase in third-quarter leasing activity, according to CBRE's U.S. Life Sciences Outlook. However, this improvement masks underlying weakness: lab leases have declined an average of 8% annually while venture capital funding has dropped 12% annually, establishing a direct structural relationship between VC investment patterns and real estate demand.
A critical constraint on sector recovery is the collapsing venture biotech allocation. Biotech's share of total U.S. venture capital has contracted from approximately 15% to just 7% in recent quarters, fundamentally constraining new lab space demand at the sector's primary margin. This compression directly correlates with broader venture capital contraction and sector risk-off positioning among institutional investors.
However, emerging trends suggest future market reorientation. AI-native biotechs now represent one-sixth of all biotech venture capital deals and demonstrate materially different spatial economics than traditional biotechs—requiring approximately one-third less space per employee with a 45-to-55 lab-to-office ratio. This architectural shift, combined with anticipated workforce growth of 50% within three years across major life sciences hubs, positions certain regional clusters as competitive winners. According to recent analysis, prime markets will differentiate on five dimensions: artificial intelligence capability, start-up ecosystem strength, biomanufacturing infrastructure, talent availability, and medtech positioning. Long-term structural advantages persist across major U.S. life sciences hubs despite current oversupply dynamics.
The immediate market reality reflects substantial dislocation. Vacancy rates have surged to 27%—a 20.4 percentage point increase over three years—creating what major real estate firms characterize as a "tenant's market." This oversupply burden falls disproportionately on newer Class A buildings delivered since early 2022, when the sector peaked. Lab leasing activity slowed dramatically in Q1 2025, though 2024 showed some recovery momentum with a notable 41% year-over-year increase in third-quarter leasing activity, according to CBRE's U.S. Life Sciences Outlook. However, this improvement masks underlying weakness: lab leases have declined an average of 8% annually while venture capital funding has dropped 12% annually, establishing a direct structural relationship between VC investment patterns and real estate demand.
A critical constraint on sector recovery is the collapsing venture biotech allocation. Biotech's share of total U.S. venture capital has contracted from approximately 15% to just 7% in recent quarters, fundamentally constraining new lab space demand at the sector's primary margin. This compression directly correlates with broader venture capital contraction and sector risk-off positioning among institutional investors.
However, emerging trends suggest future market reorientation. AI-native biotechs now represent one-sixth of all biotech venture capital deals and demonstrate materially different spatial economics than traditional biotechs—requiring approximately one-third less space per employee with a 45-to-55 lab-to-office ratio. This architectural shift, combined with anticipated workforce growth of 50% within three years across major life sciences hubs, positions certain regional clusters as competitive winners. According to recent analysis, prime markets will differentiate on five dimensions: artificial intelligence capability, start-up ecosystem strength, biomanufacturing infrastructure, talent availability, and medtech positioning. Long-term structural advantages persist across major U.S. life sciences hubs despite current oversupply dynamics.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.